Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lenvatinib plus pembrolizumab shows promising activity in NSCLC

Brose M et al. SITC 2018, Abstract P392

Key clinical point: Lenvatinib/pembrolizumab shows promise in metastatic NSCLC.

Major finding: Overall response rate at 24 weeks was 33.3%.

Study details: Interim findings in 21 patients from a phase 1b/2 study.

Disclosures: Dr. Brose has received consulting fees, research grants, and honorarium from Eisai.

Read the article here.

Citation:

Brose M et al. SITC 2018, Abstract P392